bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
85 hedge funds and large institutions have $17.1M invested in bluebird bio in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 19 closing their positions.
239% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $7M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
6.58% more ownership
Funds ownership: 29.37% → 35.95% (+6.6%)
2% more funds holding
Funds holding: 83 → 85 (+2)
28% less capital invested
Capital invested by funds: $23.8M → $17.1M (-$6.7M)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.41M |
| 2 |
CIEC
Crédit Industriel et Commercial
Paris France,
France
|
+$902K |
| 3 |
GLF
Groupe la Francaise
Paris,
France
|
+$812K |
| 4 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$666K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$680K |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$632K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$491K |
| 4 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
-$407K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$328K |
BLUE Hedge Fund Activity: Q1 2025 in Review
85 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2025, worth a combined $17.1M — down 28% from $23.8M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BLUE positions and 19 closed out — a net gain of 3 holders — while 15 added to existing stakes and 24 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.41M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $680K sold.
- 85 institutional investors held bluebird bio (BLUE) as of Q1 2025, up from 83 in Q4 2024.
- Funds reported $17.1M of bluebird bio stock for Q1 2025, down 28% quarter-over-quarter.
- 22 funds opened new bluebird bio positions in Q1 2025 and 19 closed out, a net change of +3 holders.
- The largest bluebird bio buyer in Q1 2025 was Tang Capital Management, an estimated $2.41M added.
- The largest bluebird bio seller in Q1 2025 was Avidity Partners Management, an estimated $680K sold.
Based on aggregated 13F filings for Q1 2025.